Showing 29,521 - 29,540 results of 29,839 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( 5 ((step decrease) OR (nn decrease)) ))', query time: 1.04s Refine Results
  1. 29521

    DataSheet_2_WASp Deficiency Selectively Affects the TCR Diversity of Different Memory T Cell Subsets in WAS Chimeric Mice.docx by Wenyan Li (255305)

    Published 2022
    “…Bioinformatic analyses showed that compared with wild type (WT), WAS knock out (KO)-CD4<sup>+</sup> TEM cells exhibited increased Simpson index and decreased D50 index (P <0.05); The rank abundance curve of KO-CD4<sup>+</sup> TEM cells was shorter and steeper than that of WT, and the angle of <sup>q</sup>D and q in KO-CD4<sup>+</sup> TEM cells was lower than that of WT, while these indexes showed few changes between WT and KO chimeric mice in the CD8<sup>+</sup>TCM population. …”
  2. 29522

    DataSheet_1_Dysregulation of iron metabolism modulators in virologically suppressed HIV-infected patients.docx by Vanesa Garrido-Rodríguez (14172573)

    Published 2022
    “…Since virologically suppressed chronic HIV-infected subjects under effective antiretroviral treatment (ART) exhibit a persistent immune dysfunction that leads to comorbidities, iron homeostasis may be relevant in this context. …”
  3. 29523

    datasheet1_Spatio-Temporal Variability of Peat CH4 and N2O Fluxes and Their Contribution to Peat GHG Budgets in Indonesian Forests and Oil Palm Plantations.docx by Erin Swails (10323518)

    Published 2021
    “…The objective of our research was to assess changes in peat GHG flux and budget associated with peat swamp forest disturbance and conversion to oil palm plantation and to evaluate drivers of variation in trace gas fluxes. Over a period of one and a half year, we monitored monthly CH<sub>4</sub> and N<sub>2</sub>O fluxes together with environmental variables in three undrained peat swamp forests and three oil palm plantations on peat in Central Kalimantan. …”
  4. 29524

    Data_Sheet_1_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.docx by Jiachuan Xiong (748476)

    Published 2021
    “…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”
  5. 29525

    Metabolic changes associated with AN5568 treatment. by Pieter C. Steketee (466154)

    Published 2018
    “…WT; wild type untreated, AN5568; wildtype treated for six hours at 10x EC<sub>50</sub>. C) A schematic to show the metabolites involved in methyltransferase reactions. …”
  6. 29526

    Image_2_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIFF by Jiachuan Xiong (748476)

    Published 2021
    “…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”
  7. 29527

    DataSheet_1_WASp Deficiency Selectively Affects the TCR Diversity of Different Memory T Cell Subsets in WAS Chimeric Mice.zip by Wenyan Li (255305)

    Published 2022
    “…Bioinformatic analyses showed that compared with wild type (WT), WAS knock out (KO)-CD4<sup>+</sup> TEM cells exhibited increased Simpson index and decreased D50 index (P <0.05); The rank abundance curve of KO-CD4<sup>+</sup> TEM cells was shorter and steeper than that of WT, and the angle of <sup>q</sup>D and q in KO-CD4<sup>+</sup> TEM cells was lower than that of WT, while these indexes showed few changes between WT and KO chimeric mice in the CD8<sup>+</sup>TCM population. …”
  8. 29528

    Northern blot analysis of riRNA. by Hiraku Takada (3599702)

    Published 2016
    “…The level of rRNA markedly decreased in the stationary phase. [C] <i>E</i>. <i>coli</i> BW25113 was grown in M9-glucose medium, and in the middle of exponential phase, total RNA was prepared using Isogen and subjected to Northern blot analysis using a series of Northern probes (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>, probes N01 to N10). riRNA was detected using two specific probes, probe-N3 and probe-N4 (for probes see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>; and for primers used for amplification of these probes, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.s005" target="_blank">S2 Table</a>). …”
  9. 29529

    Supplemental Material for Juurakko et al., 2021 by Collin L. Juurakko (10941459)

    Published 2021
    “…</p><p></p><p></p><p> </p><p>A list of protein accession identifications for all significantly increased and decreased proteins obtained by MS were assembled and used as inputs for STRING (version 11.0) to predict protein-protein interactions (Franceschini <i>et al.…”
  10. 29530
  11. 29531

    Effects of plant-based diets in endurance athletes: a scoping review and practical nutritional recommendations – Protocol by Diego A. Bonilla (9086201)

    Published 2023
    “…</p><p dir="ltr">iv) Full text available.</p><p dir="ltr">v) Articles that report the effects of the vegan/vegetarian diet on performance in endurance athletes.…”
  12. 29532

    Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  13. 29533

    Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  14. 29534

    Table_6_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  15. 29535

    Table_10_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  16. 29536

    Table_2_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  17. 29537

    P4HA3 deficiency increased sensitization to immune checkpoint inhibitors and P4HA3 could predict the clinical therapeutic effect of PD-1 inhibitor (Camrelizumab). by Hong Yan Huang (20135965)

    Published 2024
    “…(B) P4HA3 deficiency inhibited proliferation ability of MDA-MB-231, HCT116 and A549 cell lines by EdU assay. Scale bar: 50 μm. …”
  18. 29538

    Table_7_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  19. 29539

    Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  20. 29540

    Table_12_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”